Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 10/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 9/20 | 0.60 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.60 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.57 |
| ▸ | ATM | Q13315 | 1/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.54 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.54 |
| ▸ | TSHR | P16473 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7926306 | 1.00 | ALDH1A1 (0.60) | ALDH1A1KDM4ETDP1L3MBTL1ATM | |
| SCHEMBL4514567 | 0.92 | KDM4E (0.59) | ALDH1A1KDM4ETDP1L3MBTL1ATM | |
| SCHEMBL4517151 | 0.88 | ALDH1A1 (0.63) | ALDH1A1KDM4ETDP1L3MBTL1ATM | |
| SCHEMBL4513801 | 0.88 | ALDH1A1 (0.63) | ALDH1A1KDM4ETDP1L3MBTL1ATM | |
| SCHEMBL4521072 | 0.87 | ALDH1A1 (0.62) | ALDH1A1KDM4ETDP1L3MBTL1ATM | |
| SCHEMBL7925245 | 0.87 | ALDH1A1 (0.62) | ALDH1A1KDM4ETDP1L3MBTL1ATM | |
| SCHEMBL4514426 | 0.87 | ALDH1A1 (0.62) | ALDH1A1KDM4ETDP1L3MBTL1ATM | |
| SCHEMBL9342470 | 0.85 | KDM4E (0.60) | ALDH1A1KDM4ETDP1SMN1; SMN2 | |
| SCHEMBL7164025 | 0.85 | ALDH1A1 (0.60) | ALDH1A1KDM4ETDP1L3MBTL1ATM | |
| SCHEMBL8871715 | 0.85 | ALDH1A1 (0.60) | ALDH1A1KDM4ETDP1L3MBTL1ATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8088760-B2 | Benzoxazole carboxamide inhibitors of poly(ADP-ribose)polymerase (PARP) | BIOMARIN PHARMACEUTICAL INC. (US) | 2012-01-03 | — | — | US | disclosed |
| EP-2247600-A2 | BENZOXAZOLE CARBOXAMIDE INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE (PARP) | Lead Therapeutics, Inc. (US) | 2010-11-10 | — | — | EP | disclosed |
| US-20090258883-A1 | 1H-Indole-Pyridinecarboxamide and 1H-Indole-Piperidinecarboxamide Compounds | LES LABORATOIRES SERVIER (FR) | 2009-10-15 | — | — | US | disclosed |
| WO-2009099736-A2 | BENZOXAZOLE CARBOXAMIDE INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE (PARP) | LEAD THERAPEUTICS, INC. (US) | 2009-08-13 | — | — | WO | disclosed |
| US-20090197863-A1 | BENZOXAZOLE CARBOXAMIDE INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE (PARP) | LEAD THERAPEUTICS, INC. (US) | 2009-08-06 | — | — | US | disclosed |
| WO-2009029375-A1 | NOVEL INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE (PARP) | LEAD THERAPEUTICS, INC. (US) | 2009-03-05 | — | — | WO | disclosed |
| US-20090062268-A1 | NOVEL INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE (PARP) | LEAD THERAPEUTICS, INC. (US) | 2009-03-05 | — | — | US | disclosed |
| EP-0392803-B1 | Novel compounds | BEECHAM GROUP PLC (GB) | 2004-06-16 | — | — | EP | disclosed |
| US-6174898-B1 | TREATING FILARIAE IN LYMPHATIC SYSTEM BY ADMINISTERING N-SUBSTITUTED AZAHETEROCYCLIC CARBOXYLIC ACIDS AND ESTERS IN WHICH A SUBSTITUTED ALKYL CHAIN FORMS PART OF N-SUBSTITUENT AND SALTS | NOVO NORDISK A/S (DK) | 2001-01-16 | — | — | US | disclosed |
| EP-0858339-A1 | A METHOD OF TREATING FILARIAE | NOVO NORDISK A/S (DK) | 1998-08-19 | — | — | EP | disclosed |
| US-5039685-A | Nervous system disorders | NOVO NORDISK A/S (DK) | 1991-08-13 | — | — | US | disclosed |
| US-4988706-A | Treatment of dementia in mammals, central nervous system disorders, cognition activators | BEECHAM GROUP P.L.C. (GB) | 1991-01-29 | — | — | US | disclosed |
| EP-0402056-A2 | Azabicyclic compounds, process for their preparation and pharmaceutical compositions containing them | Beecham Group p.l.c. (GB) | 1990-12-12 | — | — | EP | disclosed |
| US-4971975-A | TREATMENT OF DEMENTIA; AZABICYCLOOCTANE COMPOUNDS | BEECHAM GROUP PLC (GB) | 1990-11-20 | — | — | US | disclosed |
| EP-0392803-A1 | Novel compounds | Beecham Group p.l.c. (GB) | 1990-10-17 | — | — | EP | disclosed |
| EP-0366304-A2 | Heterocyclic derivatives, process for their preparation and pharmaceutical compositions containing them | BEECHAM GROUP PLC (GB) | 1990-05-02 | — | — | EP | disclosed |
| EP-0342635-A1 | Azacyclic carboxylic acid derivatives, their preparation and use | NOVO NORDISK A/S (DK) | 1989-11-23 | — | — | EP | disclosed |
| EP-0339834-A2 | Heterocyclic compounds, process for their preparation and pharmaceutical compositions containing them | BEECHAM GROUP PLC (GB) | 1989-11-02 | — | — | EP | disclosed |
| EP-0338723-A1 | Novel compounds | BEECHAM GROUP PLC (GB) | 1989-10-25 | — | — | EP | disclosed |
| EP-0287356-A2 | Bridgehead substituted azabicyclic derivatives | BEECHAM GROUP PLC (GB) | 1988-10-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090197863-A1 | BENZOXAZOLE CARBOXAMIDE INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE (PARP) | PARP1, PARP2, PARP11 | ALDH1A1 398/4885KDM4E 1650/4885TDP1 67/4885 |
| US-20090062268-A1 | NOVEL INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE (PARP) | PARP1, PARP11, PARP2 | ALDH1A1 651/4885KDM4E 1849/4885TDP1 47/4885 |
| US-20090258883-A1 | 1H-Indole-Pyridinecarboxamide and 1H-Indole-Piperidinecarboxamide Compounds | IDO1, AHR, IDO2 | ALDH1A1 370/4885KDM4E 2039/4885TDP1 2926/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.